These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 12181777)
21. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453 [TBL] [Abstract][Full Text] [Related]
22. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Antoniou AC; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF J Med Genet; 2005 Jul; 42(7):602-3. PubMed ID: 15994883 [TBL] [Abstract][Full Text] [Related]
23. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414 [TBL] [Abstract][Full Text] [Related]
24. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Tonin PN Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226 [TBL] [Abstract][Full Text] [Related]
25. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627 [TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families. Sarantaus L; Auranen A; Nevanlinna H Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181 [TBL] [Abstract][Full Text] [Related]
27. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. Niell BL; Rennert G; Bonner JD; Almog R; Tomsho LP; Gruber SB J Natl Cancer Inst; 2004 Jan; 96(1):15-21. PubMed ID: 14709734 [TBL] [Abstract][Full Text] [Related]
28. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958 [TBL] [Abstract][Full Text] [Related]
29. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254 [TBL] [Abstract][Full Text] [Related]
30. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Antoniou AC; Durocher F; Smith P; Simard J; Easton DF; Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652 [TBL] [Abstract][Full Text] [Related]
31. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160 [TBL] [Abstract][Full Text] [Related]
32. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464 [TBL] [Abstract][Full Text] [Related]
33. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Foretova L; Machackova E; Navratilova M; Pavlu H; Hruba M; Lukesova M; Valik D Hum Mutat; 2004 Apr; 23(4):397-8. PubMed ID: 15024741 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Thirthagiri E; Lee SY; Kang P; Lee DS; Toh GT; Selamat S; Yoon SY; Taib NA; Thong MK; Yip CH; Teo SH Breast Cancer Res; 2008; 10(4):R59. PubMed ID: 18627636 [TBL] [Abstract][Full Text] [Related]
35. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2. Frank TS; Deffenbaugh AM; Hulick M; Gumpper K Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259 [TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511 [TBL] [Abstract][Full Text] [Related]
37. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400 [TBL] [Abstract][Full Text] [Related]
38. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933 [TBL] [Abstract][Full Text] [Related]
39. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939 [TBL] [Abstract][Full Text] [Related]
40. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Warner E; Foulkes W; Goodwin P; Meschino W; Blondal J; Paterson C; Ozcelik H; Goss P; Allingham-Hawkins D; Hamel N; Di Prospero L; Contiga V; Serruya C; Klein M; Moslehi R; Honeyford J; Liede A; Glendon G; Brunet JS; Narod S J Natl Cancer Inst; 1999 Jul; 91(14):1241-7. PubMed ID: 10413426 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]